Arcus Biosciences Announces Participation at Leerink Partners Roundtable Series: Rare Disease & Oncology
HAYWARD, Calif.--(BUSINESS WIRE)--Sep 20, 2018--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced Terry Rosen, Ph.D., Chief Executive Officer, and Jennifer Jarrett, Chief Operating Officer and Chief Financial Officer, will participate in a fireside chat at the Leerink Partners Roundtable Series: Rare Disease & Oncology on Wednesday, October 3, 2018, at 10:30 am ET at the Lotte New York Palace, in New York.
About Arcus Biosciences
Arcus Biosciences is a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies. Arcus has several programs targeting important immuno-oncology pathways, including a dual adenosine receptor antagonist AB928, which is in a Phase 1/1b program to evaluate AB928 in combination with other agents in multiple tumor types, and an anti-PD-1 antibody AB122, which is being evaluated in a Phase 1 trial and is being tested in combination with Arcus’s other product candidates. Arcus’s other programs include AB154, an anti-TIGIT antibody, which is in a Phase 1 trial to evaluate AB154 as monotherapy and in combination with AB122, and AB680, a small molecule inhibitor of CD73, which is in IND-enabling studies. Arcus has extensive in-house expertise in medicinal chemistry, immunology, biochemistry, pharmacology and structural biology. For more information about Arcus Biosciences, please visit www.arcusbio.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20180920005454/en/
CONTACT: Arcus Biosciences
Jennifer Jarrett, 510-694-6261
Nicole Arndt, 510-284-4728
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA NEW YORK
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS INFECTIOUS DISEASES ONCOLOGY PHARMACEUTICAL
SOURCE: Arcus Biosciences
Copyright Business Wire 2018.
PUB: 09/20/2018 04:05 PM/DISC: 09/20/2018 04:05 PM